Is there a need to widely prescribe antibiotics in patients hospitalized with COVID-19?
Antibiotic therapy
COVID-19
Prognosis
SARS-CoV-2
Journal
International journal of infectious diseases : IJID : official publication of the International Society for Infectious Diseases
ISSN: 1878-3511
Titre abrégé: Int J Infect Dis
Pays: Canada
ID NLM: 9610933
Informations de publication
Date de publication:
Apr 2021
Apr 2021
Historique:
received:
08
11
2020
revised:
19
01
2021
accepted:
20
01
2021
pubmed:
29
1
2021
medline:
22
5
2021
entrez:
28
1
2021
Statut:
ppublish
Résumé
Debate continues regarding the usefulness and benefits of wide prescription of antibiotics in patients hospitalized with coronavirus disease 2019 (COVID-19). All patients hospitalized in the Infectious Diseases Department, Dijon University Hospital, Dijon, France between 27 February and 30 April 2020 with confirmed COVID-19 were included in this study. Clinical, biological and radiological data were collected, as well as treatment and outcome data. An unfavourable outcome was defined as death or transfer to the intensive care unit. Patient characteristics and outcomes were compared between patients who did and did not receive antibiotic therapy using propensity score matching. Among the 222 patients included, 174 (78%) received antibiotic therapy. The univariate analysis showed that patients who received antibiotic therapy were significantly older, frailer and had more severe presentation at admission compared with patients who did not receive antibiotic therapy. Unfavourable outcomes were more common in patients who received antibiotic therapy [hazard ratio (HR) 2.94, 95% confidence interval (CI) 1.07-8.11; P = 0.04]. Multi-variate analysis and propensity score matching indicated that antibiotic therapy was not significantly associated with outcome (HR 1.612, 95% CI 0.562-4.629; P = 0.37). Antibiotics were frequently prescribed in this study and this was associated with more severe presentation at admission. However, antibiotic therapy was not associated with outcome, even after adjustment. In line with recent publications, such data support the need to streamline antibiotic therapy in patients with COVID-19.
Sections du résumé
BACKGROUND
BACKGROUND
Debate continues regarding the usefulness and benefits of wide prescription of antibiotics in patients hospitalized with coronavirus disease 2019 (COVID-19).
METHODS
METHODS
All patients hospitalized in the Infectious Diseases Department, Dijon University Hospital, Dijon, France between 27 February and 30 April 2020 with confirmed COVID-19 were included in this study. Clinical, biological and radiological data were collected, as well as treatment and outcome data. An unfavourable outcome was defined as death or transfer to the intensive care unit. Patient characteristics and outcomes were compared between patients who did and did not receive antibiotic therapy using propensity score matching.
FINDINGS
RESULTS
Among the 222 patients included, 174 (78%) received antibiotic therapy. The univariate analysis showed that patients who received antibiotic therapy were significantly older, frailer and had more severe presentation at admission compared with patients who did not receive antibiotic therapy. Unfavourable outcomes were more common in patients who received antibiotic therapy [hazard ratio (HR) 2.94, 95% confidence interval (CI) 1.07-8.11; P = 0.04]. Multi-variate analysis and propensity score matching indicated that antibiotic therapy was not significantly associated with outcome (HR 1.612, 95% CI 0.562-4.629; P = 0.37).
CONCLUSION
CONCLUSIONS
Antibiotics were frequently prescribed in this study and this was associated with more severe presentation at admission. However, antibiotic therapy was not associated with outcome, even after adjustment. In line with recent publications, such data support the need to streamline antibiotic therapy in patients with COVID-19.
Identifiants
pubmed: 33508478
pii: S1201-9712(21)00062-X
doi: 10.1016/j.ijid.2021.01.051
pmc: PMC7839401
pii:
doi:
Substances chimiques
Anti-Bacterial Agents
0
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
256-260Informations de copyright
Copyright © 2021 The Authors. Published by Elsevier Ltd.. All rights reserved.
Références
N Engl J Med. 2020 Apr 30;382(18):1708-1720
pubmed: 32109013
Int J Infect Dis. 2019 Apr;81:184-190
pubmed: 30690213
Immunity. 2020 Jul 14;53(1):19-25
pubmed: 32610079
Emerg Med J. 2018 Jun;35(6):345-349
pubmed: 29467173
Clin Infect Dis. 2020 Dec 3;71(9):2459-2468
pubmed: 32358954
Lancet Infect Dis. 2020 Jun;20(6):697-706
pubmed: 32224310
Stem Cell Rev Rep. 2020 Jun;16(3):434-440
pubmed: 32307653
Nature. 2020 Mar;579(7798):265-269
pubmed: 32015508
JAMA. 2020 Apr 7;323(13):1239-1242
pubmed: 32091533
Int J Infect Dis. 2012 May;16(5):e321-31
pubmed: 22387143
Diagnosis (Berl). 2020 May 26;7(2):91-96
pubmed: 32352401
N Engl J Med. 2012 May 17;366(20):1881-90
pubmed: 22591294
JAMA. 2020 Aug 25;324(8):782-793
pubmed: 32648899
Drugs. 2020 Sep;80(13):1267-1292
pubmed: 32696108
Autoimmun Rev. 2020 Jul;19(7):102568
pubmed: 32376398
Antiviral Res. 2017 Aug;144:48-56
pubmed: 28535933
JAMA. 2016 Feb 23;315(8):801-10
pubmed: 26903338
JAMA. 2020 May 26;323(20):2052-2059
pubmed: 32320003
Front Immunol. 2020 Jun 16;11:1446
pubmed: 32612617
J Microbiol Immunol Infect. 2019 Dec;52(6):872-879
pubmed: 31759853
Lung. 2018 Jun;196(3):359-361
pubmed: 29541854
Int J Antimicrob Agents. 2018 Jun;51(6):918-924
pubmed: 29501821
J Intern Med. 2020 Sep;288(3):335-344
pubmed: 32352202
Eur Respir J. 2020 May 7;55(5):
pubmed: 32269088
Influenza Other Respir Viruses. 2016 Sep;10(5):394-403
pubmed: 27232677